Superoxide release by human polymorphonuclear leukocytes in the presence of deferoxamine

Haematologica

Volumn 82, Issue 4, 1997, Pages 411-414

  Iacobini, Metello ^a   Palumbo, Giuseppe ^b   Cassiani, Flaminia ^b   Perla, Francesco Massimo ^a   Werner, Beate ^a   Menichelli, Adriana ^b   Del Principe, Domenico ^b  

^a SAPIENZA UNIVERSITY OF ROME   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Cytochrome c reduction; NBT; Reactive oxygen species; Superoxide ion

Indexed keywords

CYTOCHROME C; DEFEROXAMINE; DEFEROXAMINE MESYLATE; REACTIVE OXYGEN METABOLITE; SUPEROXIDE;

ARTICLE; CHELATION; DENSITOMETRY; DRUG EFFICACY; DRUG SAFETY; HUMAN; HUMAN CELL; IRON OVERLOAD; LEUKOCYTE ACTIVATION; NEUTROPHIL; RISK ASSESSMENT; TISSUE INJURY;

ANTIDOTES; CELLS, CULTURED; DEFEROXAMINE; HUMANS; NEUTROPHIL ACTIVATION; NEUTROPHILS; REACTIVE OXYGEN SPECIES; SUPEROXIDES;

EID: 0031452029     PISSN: 03906078     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Keberle H. The biochemistry of desferrioxamine and its relation to iron metabolism. Ann NY Acad Sci 1964; 119:758-68.
2. Cohen AR, Mizarin J, Schwartz E. Rapid removal of excessive iron with daily, high-dose intravenous chelation therapy. J Pediatr 1989; 115:151-5.
3. Caziev D, Giardini C, Angelucci E, et al. Intravenous chelation therapy during transplantation for thalassemia. Haematologica 1995; 80:300-4.
4. Donfrancesco A, Deb G, Dominici JC, et al. Effects of a single course of deferoxamine in neuroblastoma patients. Cancer Res 1990; 50: 4929-30.
5. Donfrancesco A, Deb G, De Sio L, et al. Role of deferoxamine in tumor therapy. Acta Haematol 1996; 95:66-9.
6. Weinberg K, Novel use of deferoxamine. Am J Pediatr Hematol Oncol 1990; 12:9-13.
7. Freedman MH, Grisaru D, Olivieri N, et al. Pulmonary syndrome in patients with thalassemia major receiving intravenous deferoxamine infusions Am J Dis Child 1990; 144:565-9.
8. Tenenbien M, Kowalski S, Sienko A, et al. Pulmonary toxic effects of continuous desferrioxamine administration in acute iron poisoning. Lancet 1992; 339:699-701.
9. Weitman SD, Buchanan GR, Kaman BA, et al. Pulmonary toxicity of deferoxamine in children with advanced cancer. J Natl Cancer Inst 1991; 83:1834-5.
10. Royal JA, Levin DL. Adult respiratory distress syndrome in pediatric patients. I. Clinical aspects, pathophysiology, pathology, and mechanism of lung injury. J Pediatr 1988; 112:169-80.
11. Tate RM, Repine JE, Neutrophils and the adult respiratory distress syndrome. Am Rev Respir Dis 1983; 128:552-8.
12. Repine JE, Bowman CM, Tate RM. Neutrophils and lung edema. Chest 1982; S81:47-50.
13. Deneke SM, Fanburg BL, Normobaric oxygen toxicity of the lung. N Engl J Med 1980; 303:76-86.
14. Boyum A. Separation of leukocytes from blood and bone marrow. Scand. J Lab Clin Invest 1968; 21:77-97.
15. English D, Andersen BR. Single step separation of blood cells. Granulocyte and mononuclear leukocytes on discontinuous density gradients of Ficoll-Hypaque. J Immunol Methods 1974; 5:249-52.
16. van Asbeck BS, Marx JM, Struyvenberg A, et al. Deferoxamine enhances phagocytic function of human polymorphonuclear leukocytes. Blood 1984; 63:714-20.
17. Iacobini M, Torre A, Palumbo G, et al. Study of chronic granulomatous disease by a nitroblue tetrazolium densitometric kinetic test: a new research method. Clin Chim Acta 1993; 221:197-202.
18. Iacobini M, Palumbo G, Bartolozzi S, et al. Superoxide production by neutrophils in children with malignant tumors treated with recombinant human granulocyte colony-stimulating factor. Haematologica 1995; 80:13-7.
19. Cohen HJ, Chovianec ME. Superoxide generation by digitonin-stimulated guinea pig granulocytes: a basis for a continuous assay for monitoring superoxide production and for the study of activation of the generating system. J Clin Invest 1978; 61:1081-7.
20. Dahle LK, Hill EG, Holman RT. The thiobarbituric acid reaction and the autoxidations of polyunsaturated fatty acid methyl esters. Arch Biochem Biophys 1962; 98:253-61.
21. Hoe S, Rowley DA, Halliwell B. Reactions of ferrioxamine and desferrioxamine with the hydroxyl radical. Chem Biol Interact 1982; 41:75-87.
22. Sinaceur J, Ribiere C, Abumurad C, et al. Reduction in the rate of ethanol elimination in vivo by desferrioxamine and diethylenetriaminepentaacetic acid: suggestion for involvemente of hydroxyl radicals in ethanol oxidation. Biochem Pharmacol 1983; 32:2371-3.
23. Sinaceur J, Ribiere C, Nordmann J, et al. Desferrioxamine a scavenger of superoxide radicals? Biochem Pharmacol 1984; 33:1693-4.
24. Haber F, Weiss J. The catalytic decomposition of hydrogen peroxide by iron salts. Proc R Soc London (A). 1934; 147:332-51.
25. Koppenol WH, Butler J, van Leeuwen JW. The Haber-Weiss cycle. Photochem Photobiol 1978; 28:655-63.
26. McPhail LC, Snyderman R. Activation of the respiratory burst enzyme in human polymorphonuclear leukocytes by chemoattractants and other soluble stimuli. J Clin Invest 1983; 72:192-200.
27. Nishizuka Y. The molecular heterogeneity of protein kinase C and its implication for cellular regulation. Nature 1988; 334; 661-5.
28. Sullivan R, Griffin JD, and Malech HL. Acquisition of formyl peptide receptors during normal human myeloid differentiation. Blood 1987; 70:1222-4.
29. McLeish KR, Gierschik P, Schepers T, Sidiropoulos D, Jakobs KH. Evidence that activation of common G-protein by receptors for leukotriene B4 and N-formylmethionyl-leucyl-phenylalanine in HL-60 cells occurs by different mechanisms. Biochem J 1989; 260:427-34.
30. Chanock SJ, El Benna J, Smith RM, et al. The respiratory burst oxidase. J Biol Chem 1994; 269:24519-222.
31. Tauber Al. Protein kinase C and the activation of the human neutrophil NADPH-oxidase. Blood 1987; 69:711-20.
32. Kessels GCR, Krause K, Verhoeven AJ. Protein kinase C activity is not involved in N-formylmethionyl-leucyl-phenylalanine-induced phospholipase D activation in human neutrophils, but is essential for concomitant NADPH oxidase activation: studies with a staurosporine analogue with improved selectivity for protein kinase C. Biochem J 1993; 292:781-5.